Biotech Stock Report 10.03.09
Tuesday, 10 March, 2009
The pharmaceuticals and biotechnology sector was mostly flat recording a small 0.11% increase for the day.
Market heavyweight CSL (ASX:CSL) was stable, up 28c to $35.44.
Living Cell Technologies (ASX:LCT) recorded spectacular increase of 31%, to close at 10.5c but is still trading near its 52 week low of 8c.
Prana Biotechnology (ASX:PBT) and IDT Australia (ASX:IDT) were among the day's weaker performers in the pharmaceuticals and biotechnology sector, down 8% and 6% respectively with Bionomics Limited (ASX:BNO) not far behind, 5% down to 20c.
Chemgenex Pharmaceuticals (ASX:CXS) recorded a solid 6% rise to 34c, but is still well down on its 52 week high of $1.25. Novogen and Progen also moved up over 3%.
Inhaled form of blood thinner treats serious COVID infections
Heparin has traditionally been injected and used to treat blood clots, but the new study tested...
Next-gen therapies could treat high-grade gliomas
Government funding will enable researchers to test a suite of next-generation therapies they have...
Bacteriophage cocktail to combat superbugs
Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...
